Cargando…
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...
Autores principales: | Bernhard, Sonja, Kaiser, Marcel, Burri, Christian, Mäser, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589988/ https://www.ncbi.nlm.nih.gov/pubmed/36278589 http://dx.doi.org/10.3390/diseases10040090 |
Ejemplares similares
-
Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole
por: Neau, Philippe, et al.
Publicado: (2020) -
Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
por: Valverde Mordt, Olaf, et al.
Publicado: (2022) -
Modelling the impact of fexinidazole use on human African trypanosomiasis (HAT) transmission in the Democratic Republic of the Congo
por: Das, Aatreyee M., et al.
Publicado: (2021) -
The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019) -
Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: A Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)